INTRODUCTION
Far reaching conclusions have been drawn from the observation that females with cancer of the cervix have higher antibody titres against herpes simplex virus (HSV)-2 than HSV-1 (Rawls et al., 1968) . This correlation was recently questioned (Vonka et al., 1984a, b) . Recent results suggest that HSV-2 may influence the humoral antibody levels by immunosuppression (Kampe et al., 1985; Nick et al., 1986) and consequently the local microepidemiology of HSV-2 may be affected.
We were studying the kinetics and genetics of HSV-l-induced antibody formation in mice (Knoblich et al., 1983) and tested the possibility of enhancement of antibody formation (Knoblich et al., 1984) . Surprisingly, only very low levels of antibodies were obtained after infection with four different strains of HSV-2 (Kampe et al., 1985) . Some intertypic recombinants also induced only low levels of antibodies. Finally, infectious HSV-2 but not HSV-1 was able to induce suppression of humoral antibody formation against HSV-1 and -2 (Kampe et al., 1985; Nick et al., 1986) . It was demonstrated by injection of silica that macrophages were the first target, since silica could release the suppression .
The HSV-2-induced suppression phenomenon of antibody formation was therefore studied at the level of B cells producing HSV-specific IgM or IgG antibodies. The main purpose of the present communication was to elucidate more exactly the mechanism by which HSV-2 might interrupt antibody generation.
Cells and viruses. HSV-1 strain Len and HSV-2 strains HG-52 and Bry were used. The properties of these virus strains were described previously (Kampe et al., 1985; Nick et al., 1986) . For infection of mice, virus was propagated on confluent monolayers of Veto cells grown in Medium 199 (Gibco) supplemented with 10% heatinactivated newborn calf serum. Titres of the virus stocks were determined by plaque assays on Vero cells (Kampe et al., 1985) .
For preparation of antigen, virus was grown on BHK-21 cells in GMEM (Gibco) with 10% newborn calf serum (Gibco). For most immunospot assays HSV-1 was used as antigen; essentially identical results were obtained using HSV-2.
Preparation of antigen. The procedure used was described recently . In brief, 48 h after the infection of BHK cells, the culture supernatants were harvested and centrifuged for 20 rain (2500 g). Infected BHK cells were disrupted by repeated freezing and thawing. Comparable supernatants of non-infected BHK cells served as control antigen.
The virus particles of the supernatant were pelleted in an SW27 rotor (100000 g, 1 h). The pellet was carefully resuspended in phosphate-buffered saline (PBS) and layered onto 15 ml of 30% sucrose (w/w) in PBS. After a second centrifugation, the protein sediment was resuspended in PBS containing 0-1% NP40 by sonication. In the case of control antigen the 100000 g pellet was adjusted to the same protein concentration as the virus antigen.
Enzyme-linked immunospot assay. Antibody-secreting cells were determined according to the protocol of Sedgwick & Holt (1983) . In brief, 5 cm Petri dishes (Nunc) were coated with HSV antigen or control antigen for 12 to 18 h at 5 °C. In general, 50 ~tg of protein per dish was sufficient. The dishes were washed twice with PBS to remove unadsorbed material and exposed to PBS containing 1.5~ bovine serum albumin (BSA) (w/v) for 2 h at room temperature.
Cell suspensions were prepared by using the pooled spleens of three mice per assay. After mincing, the material was passed through a steel sieve. Cells of this suspension were pelleted (400 g, 5 rain) and the erythrocytes lysed with 0-83~ ammonium chloride. After two washes with Hanks' balanced salt solution, viable cells were counted by the trypan blue exclusion method. Spleen cells were diluted in RPMI 1640 medium with 10~ calf serum and 330 ~tl of each dilution was added to the dishes. The dishes were placed for 5 h at 37 °C in a vibration-free incubator. To remove lymphocytes the dishes were washed carefully three times with PBS and three times with PBS containing 0.05~ Tween 20. For visualization of secreted and bound antibodies, the dishes were incubated with alkaline phosphatase-conjugated goat anti-mouse IgM or IgG ~-or ~,-chain-specific; Zymed Laboratories, San Francisco, Ca., U.S.A.) for 2 h at 37 °C. Dishes were rinsed again and blue spots developed after addition of 1 ml of 2.3 mM-5-brom~4-chloro-3-indolylphosphate (Sigma) in aminomethylpropanol buffer mixed with agarose (Sedgwick & Holt, 1983) . Blue spots could be counted after 1 h at 37 °C under low magnification.
Most important for the immunospot test was the concentration of the antigen used for coating, the quality of the alkaline phosphatase-conjugated anti-mouse sera and the time of incubation.
The optimal concentration of antigen was determined by a chequerboard test. Spleen cells were obtained from animals immunized with 1 x 103 p,f.u. HSV-I (Len) 12 days before. The optimal time for detecting immunospots was found to be after 5 to 6 h of incubation. The same procedure proved to be useful for HSV-2 antigen. Specificity of the immunospot assay. In order to test the specificity of the assay system, spleen cells from HSV-1-immunized mice were tested for antibody formation against BHK control antigen.
Spleen cells from mice immunized 4 days before with sheep red blood cells were tested on HSV-1 antigen and control antigen. The assay proved to be specific for HSV. Comparing the number of immunospots from BALB/c or NMRI mice, we noted a greater homogeneity of the spot number in the inbred BALB/c females. NMRI mice produced somewhat higher numbers of antibody-secreting cells. There was no detectable difference in the size of the spots if HSV-I or HSV-2 was used as catching antigen.
Neutralization-test. The method was used as described before (Kampe et al., 1985; Knoblich et al., 1983 Knoblich et al., , 1984 Nick et al., 1986) . Approximately 20 to 30 p.f.u, was used for the neutralization reaction. Five mice were used per group. The values are given + S.D.
RESULTS

Primary infections by HSV-1 and -2
We first studied the number and time of appearance of IgM-and IgG-secreting cells after primary infection of BALB/c mice with 1 x 103 p.f.u, of HSV-1 (strain Len). Fig. 1 shows the increase in the number of IgM-producing B cells from days 5 to 12. IgG-producing cells were detected until day 20. In contrast, the same dose of HSV-2 did not induce antibody-forming B cells (Fig. 2) . Moreover, no increase in the total number of spleen cells was observed if compared to HSV-1.
We next studied the number of B cells in dose-response experiments as described earlier for humoral antibody formation. =~ 400 4 5 6 7 8 9 5 6 7 8 9 5 6 7 8 9
Time after primary int'ectiorts (days) mice with 1 × 102, 5 × 103 or 1 × l0 s p.f.u, of HSV-1 (strain Len). It could be seen that if the dose of HSV was increased, an increase of the number of IgG-producing B cells could be detected. In BALB/c mice (data not shown) a comparable increase of antibody-generating cells was observed, however at a lower level compared to NMRI mice. Fig. 4 shows low levels of IgM-and IgG-producing B ceils of BALB/c mice after infection with increasing doses of HSV-2 (strain HG-52). Additionally, it was observed that the IgM and IgG cell responses were delayed compared to antibody-secreting B cells after HSV-I infection. It should be noted that a high dose of this strain of HSV-2 (1 × 105 p.f.u.) produced disease in many mice. In control experiments (data not shown) all surviving mice exhibited HSV straintypical humoral antibody formation after infection with HSV-1 or -2.
Duration of the HSV-2-induced suppression
Suppression of antibody generation was first detectable on day 5 and was most pronounced 8 days after infection with HSV-2 . We therefore determined the duration of this suppression by using HSV-2 (strain Bry) which, because of its low pathogenicity, did not kill mice at doses of 10 ~ and 106 p.f.u, and could therefore be used for long term testing of antibody production. Table 1 shows the course of antibody formation after long term testing of mice Antibody formation was detectable 51 and 61 days after infection (1 x 106 p.f.u.) but not earlier. These results indicated that the suppression induced by HSV-2 disappeared later than 40 days after infection.
Secondary infection at day 8
The next question was whether secondary infections with different doses of HSV-1 or HSV-2 on day 8 after primary infections induced secondary B cell reactions. A high dose of a HSV-1 homologous re-infection in BALB/c mice (1 x l06 p.f.u.) induced only a minor booster cell response (Fig. 5a) . No response was observed after re-infection with 5 x l03 p.f.u. (Fig. 5b) .
However, there-was a typical booster reaction if humoral antibody formation was tested in NMRI mice after a second injection followed a primary dose of 1 x 103 p.f.u. (Table 2 , group A).
Pre-infection with HSV-2 (1 x 103 p.f.u., strain HG-52) and second infections with either t Eight mice were infected, three died. :~ Seven mice were infected, one died.
5 × 103 p.f.u, or 1 x 106 of HSV-1 showed only a cellular reaction with 1 x 106 p.f.u, of HSV-1 (Fig. 5 c and d ). This B cell response, however, was low compared to a primary HSV-1 infection and was characterized by only some IgM-and IgG-producing cells. A second injection with HSV-2 (1 × 103 or 1 x 106 p.f.u.) irrespective of the dose resulted in no B cell response (data not shown). A second experiment of this type (as Fig. 5a to d) gave identical results, with the exception that in the experiment corresponding to Fig. 5 (c) the response was still lower. The results of Fig. 5 (c) may be compared to the levels of humoral antibodies of group C in Table 2 .
Booster infections at 21, 28 and 35 days after infection
Homologous booster infections by HSV-1 at day 8 produced only a weak B cell response in the spleen (see above), whereas the level of humoral antibodies was increased independently of the time of the second injection (day 8, 21, 28 or 35) (Kampe et al., 1985; Nick et al., 1986;  Table 2 ).
Moreover, at day 21 (group F) the degree of HSV-2 (1 x 10 ~ or I x 105 p.f.u, ofbooster)-induced suppression was lower than at day 8 ( Table 2 , group E). A single injection with 1 × 105 p.f.u, of strain HG-52 induced limited antibody formation (Table 2 , group D), as described earlier (Kampe et al., 1985) . We therefore compared the number of antibody-secreting B cells after secondary infections (low or high dose of HSV-1 or -2) at 21, 28 and 35 days after infection to the humoral antibody levels (Table 2 and Fig. 5) .
A low dose homologous booster of HSV-1 administered to BALB/c mice (Table 3, resulted in a high number of antibody-secreting cells (Table 3 , groups B and D). IgM-producing cells were also detected in group B, indicating no suppression. This result contrasted with the almost complete lack of IgM-and IgG-producing cells at day 8 in the spleens of mice inoculated with 106 p.f.u, of HSV-I after a primary dose of 103 p.f.u, of HSV-1 (Fig. 5a , homologous high dose booster). A high dose booster with HSV-2 at day 28 after HSV-1 priming (group E) gave a considerable cell IgG response as expected. Group F gave the data of a high dose HSV-1 booster at day 28 after HSV-2 priming. Only a low IgG reaction was induced by the suppressing HS¥-2 primary infection. This result may be compared to Fig. 2 of Nick et al. (1986) . Group C of Table  3 gives the values for a high dose booster (HSV-2). In this case no IgM-secreting cells but considerable numbers of IgG-secreting cells could be observed. It should be added that a high dose booster with HSV-1 at day 35 (compare Table 3 , groups B and D) always gave strong HSVspecific cellular reactions in the spleen, whereas a low dose booster gave no reaction. Similar reactions in the spleen could be observed after a double homologous booster (at 21 and 42 days after infection) with either low or high doses of HSV-1 (data not shown). Generally it could be observed that the B cell booster response after HSV-2 priming was delayed compared to HSV-1 priming. averages from three BALB/c
DISCUSSION
The object of this study was to determine the kinetics of IgM-and IgG-producing B cells after HSV-1 and -2 infections in the spleen using an immunospot test supplemented by results on formation of neutralizing antibodies. By this experimental design we intended to obtain more insight into the mechanism of the HSV-2-induced suppression of humoral antibody formation (Kampe et al., 1985; Nick et al., 1986) .
Dose response experiments of primary infections with HSV-1 resulted in typical responses of IgM-and IgG-producing cells 5 to 20 days after infection. In contrast, HSV-2 induced only very low numbers of HSV-specific IgM-or IgG-producing B cells. This observation coincided clearly with earlier results on humoral antibody formation (Kampe et al., 1985; Nick et al., 1986) and Table 2 . Compared to the lymphocytic choriomeningitis virus system (Moskophidis & Lehmann-Grube, 1984 ) the number of HSV-specific antibody producing cells was rather low in BALB/c mice. However, they produced lower HSV-specific antibody serum titres than NMRI mice.
Concerning the total number of spleen cells, HSV-2 induced no or a lower response than HSV-1 (Nick, 1986; Nick et al., 1986) . This observation is supported by the experiments presented here and may be explained by a lack of certain lymphokines for cellular proliferation after HSV-2 infections. Interestingly, silica given separately induced an increase in the number of spleen cells at days 6 to 10 (data not shown) and, moreover, released the HSV-2-induced suppression probably by influencing macrophages .
Primary infections (low dose) and homologous re-infections (high dose) with HSV-I at day 8 produced only a weak B cell response in the spleen. However, typical HSV-t booster reactions (low dose) of humoral antibodies could be elicited if a low dose of HSV-1 was given 8 days after primary low dose infections. We therefore assume an extra-splenic localization of antibodyforming cells under these conditions. It is known that after priming, B cells migrate from the spleen to other locations (Van Rooijen et al., 1986) . In contrast, re-infections at days 21, 28 and 35 (only high doses of virus) resulted in strong, specific cellular secondary responses in the spleen. This indicates that 8 days after HSV-1 infection in the spleen, but not in the remainder of the organism, a state of HSV-induced non-reactivity exists, which disappears within 10 days.
Suppression of humoral antibody formation is most effective 8 days after HSV-2 infection . No booster cell response or antibody formation after HSV-2 booster infections was detectable early after challenge. The HSV-2-induced suppression of humoral antibodies lasts for about 40 days after infection with a high dose of strain Bry (1 × 106 p.f.u.). After this time humoral antibodies against HSV-2 appear spontaneously. Therefore, priming and memory should be intact. Even at day 21 a reduction of the suppression was observed ( Table  2 , group E and F). In contrast, strain HG-52 induced some humoral antibodies at a dose of 1 × 105 (Kampe et al., 1985) ; consequently, the degree of suppression seems to be different from strain to strain of HSV-2.
At days 21, 28 and 35 a limited cellular booster could be seen (Table 3) , The response was of the IgG cell type, no IgM-producing cells were detected. These results point to the stability of the priming events. Perhaps memory cells are also generated after induction of non-antibodyproducing primary infections. Additionally, there is a delay in the appearance of IgG antibodyproducing cells. The HSV-2-induced suppression may thus be caused by a block at different stages of antibody formation including macrophages and perhaps connected to a lack of proliferation of T helper cells or overproduction of suppressor cells. The existence of suppressor cells for HSV-1 humoral antibody generation was indicated by use of a low dose of cyclophosphamide (Knoblich et al., 1984) . Such cells were also observed for HSV-induced delayed type hypersensitivity (Nash et aL, 1985) .
We hope that further analysis of the HSV-2-induced suppression phenomenon will enable us to elucidate the cellular and/or lymphokine defects as well as the HSV-2-induced peculiarities of the host-parasite relationship.
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